Home / Market News / $HAE
benzinga Corporate Catalyst Impact 55/100 ● positive

BTIG Maintains Buy on Haemonetics, Raises Price Target to $130

Oct 8, 2026, 6:18 PM UTC · Primary ticker $HAE

BTIG analyst Marie Thibault reiterated a Buy rating on Haemonetics (HAE) and increased the price target from $110 to $130. This indicates a positive outlook from the analyst, suggesting potential upside for the stock based on their updated valuation.

BTIG analyst Marie Thibault maintained a 'Buy' rating on Haemonetics (HAE) and raised the price target from $110 to $130. This action signals increased confidence from the analyst in HAE's future performance and valuation. For traders, this could be seen as a short-term positive catalyst, potentially leading to increased buying interest. The long-term implication is a reinforced positive sentiment around the company, though the actual impact depends on broader market conditions and company execution. A key opportunity for traders is to capitalize on any immediate upward movement, while a risk could be if the market does not react as expected or if other negative news emerges.

$HAE positive Analyst price target increase
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.